A pioneering medical trial has discovered that administering stem cells to unborn babies suffering from spina bifida during corrective surgery can be a "important advancement" in managing prenatal disorders.
Trial Details and Safety
The American study involved six unborn babies with the 'open' form of spina bifida. Surgeons applied placenta-derived mesenchymal stem cells to the surface of the baby's spinal cord as part of the surgical correction.
Importantly, the stem cell application was found to be safe. Doctors verified that the therapy did not induce tumors, disrupt the healing process, or block the correction of related neurological issues.
Promising Outcomes
Imaging conducted after delivery confirmed a full resolution of Chiari malformation in each of the babies. This brain structure normalization is strongly associated with enhanced physical outcomes.
"If it makes additional babies to achieve ambulation who previously could not, it could establish itself as their standard of care," said the lead researcher. "These findings are profoundly encouraging and create a pathway toward lots of potential innovative interventions."
Broader Impact and Encouragement
Commentators reviewing the findings proposed that additional validation of these observed advantages could signal a "fresh chapter" in in-utero treatment. The prospect of enhancing neurological damage seen in utero is considered a transformative goal.
Notably important would be better management of bladder and bowel function, which are common challenges for individuals living with this defect.
Looking Ahead
Despite this being a first-in-human effort focused on a handful of cases, its safety demonstration and positive signals offer a robust platform for broader investigative efforts. The addition of cellular treatment with established fetal surgery techniques holds considerable promise for changing life trajectories for babies yet to be born with myelomeningocele.